Evolving therapeutic strategies for severe fever with thrombocytopenia syndrome: from past to future DOI Creative Commons
Yuxi Zhao, Xiaoxin Wu, Xinyu Wang

et al.

Therapeutic Advances in Infectious Disease, Journal Year: 2025, Volume and Issue: 12

Published: May 1, 2025

Severe fever with thrombocytopenia syndrome (SFTS) is a hemorrhagic caused by Bandavirus dabieense. SFTS was first identified in China 2009 and has been reported since then neighboring countries regions. The clinical manifestations of include fever, thrombocytopenia, leukocytopenia are often accompanied gastrointestinal symptoms bleeding. In severe cases, patients experience life-threatening immune damage cytokine storms. Despite nearly 15 years its discovery, no effective vaccine approved. However, significant progress achieved elucidating the mechanisms host responses, implementation various therapeutic agents. This article provides comprehensive review commonly utilized treatments supported current evidence. Favipiravir advantages over ribavirin terms viral clearance prognosis. Conventional immunomodulators like interferon, intravenous immunoglobulin, glucocorticoids have limited effects may even worsen conditions, whereas novel such as tocilizumab ruxolitinib shown potential for improving Prophylactic platelet transfusions neither prevent bleeding nor improve outcomes. Additionally, plasma exchange, calcium channel blockers, arginine can laboratory values expedite clearance. future, screening Food Drug Administration-approved drugs conducting multiomics analyses lead to discovery new options.

Language: Английский

The YTHDF3-DT/miR-301a-3p /INHBA axis attenuates autophagy-dependent ferroptosis in lung adenocarcinoma DOI
Peng Xiong,

Rui Yang,

Christopher Wang

et al.

Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217503 - 217503

Published: Jan. 1, 2025

Language: Английский

Citations

1
Regulation of Iron Metabolism in Ferroptosis: from Mechanism Research to Clinical Translation DOI Creative Commons
Xin Zhang, Xiang Yang, Qingyan Wang

et al.

Journal of Pharmaceutical Analysis, Journal Year: 2025, Volume and Issue: unknown, P. 101304 - 101304

Published: April 1, 2025

Language: Английский

Citations

0
Identification of lurasidone as a potent inhibitor of severe fever with thrombocytopenia syndrome virus by targeting the viral nucleoprotein DOI Creative Commons
Ting Cheng,

Qingcui Xiao,

Jing Cui

et al.

Frontiers in Microbiology, Journal Year: 2025, Volume and Issue: 16

Published: April 28, 2025

Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging tick-borne bunyavirus that causes acute febrile illness and a high mortality rate in humans. Currently, no specific antiviral agents have been approved for the prevention or treatment of SFTSV infection. The viral nucleoprotein (NP) critical component involved RNA replication transcription, representing promising target drug development. We performed structure-based virtual screening FDA-approved library using AutoDock Vina, aiming to identify potential inhibitors targeting RNA-binding pocket NP. Promising candidates were further evaluated activity vitro. Among screened compounds, lurasidone exhibited strong against SFTSV, IC50 value 4.552 μM selectivity index (SI) greater than 10, indicating favorable potency low cytotoxicity. Mechanistic investigations suggest may exert its inhibitory effect by directly binding NP, thereby interfering genome replication. This study identifies as candidate NP provides theoretical basis repurposing drugs infections. These findings offer new insights into therapeutic strategies SFTSV.

Language: Английский

Citations

0
Evolving therapeutic strategies for severe fever with thrombocytopenia syndrome: from past to future DOI Creative Commons
Yuxi Zhao, Xiaoxin Wu, Xinyu Wang

et al.

Therapeutic Advances in Infectious Disease, Journal Year: 2025, Volume and Issue: 12

Published: May 1, 2025

Severe fever with thrombocytopenia syndrome (SFTS) is a hemorrhagic caused by Bandavirus dabieense. SFTS was first identified in China 2009 and has been reported since then neighboring countries regions. The clinical manifestations of include fever, thrombocytopenia, leukocytopenia are often accompanied gastrointestinal symptoms bleeding. In severe cases, patients experience life-threatening immune damage cytokine storms. Despite nearly 15 years its discovery, no effective vaccine approved. However, significant progress achieved elucidating the mechanisms host responses, implementation various therapeutic agents. This article provides comprehensive review commonly utilized treatments supported current evidence. Favipiravir advantages over ribavirin terms viral clearance prognosis. Conventional immunomodulators like interferon, intravenous immunoglobulin, glucocorticoids have limited effects may even worsen conditions, whereas novel such as tocilizumab ruxolitinib shown potential for improving Prophylactic platelet transfusions neither prevent bleeding nor improve outcomes. Additionally, plasma exchange, calcium channel blockers, arginine can laboratory values expedite clearance. future, screening Food Drug Administration-approved drugs conducting multiomics analyses lead to discovery new options.

Language: Английский

Citations

0